Xvivo Perfusion AB (publ) (XVIPF) Financials

XVIPF Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 257.9 million 31.3 million
Dec. 31, 2025 257.2 million 28.2 million
Sept. 30, 2025 250.7 million 29.9 million
June 30, 2025 252.5 million 31.3 million

XVIPF Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 6.8 million ?
Dec. 31, 2025 9.4 million ?
Sept. 30, 2025 ? ?
June 30, 2025 930660 ?

XVIPF Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 4.5 million
Dec. 31, 2025 3.4 million
Sept. 30, 2025 457591
June 30, 2025 -353731

XVIPF Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 32.2 million - -
Dec. 31, 2025 31.6 million 12.3 million 12.3 million
Sept. 30, 2025 29.5 million 12.1 million 12.1 million
June 30, 2025 34.2 million - 10.9 million

XVIPF Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 3.3 million
Dec. 31, 2025 3.4 million
Sept. 30, 2025 3.4 million
June 30, 2025 3.3 million

XVIPF Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 3.8 million 10.7 million 7.7 million
Dec. 31, 2025 9.4 million 2.7 million 10.2 million 8.1 million
Sept. 30, 2025 2.1 million 2.5 million 8.8 million -
June 30, 2025 - 3.4 million 10.0 million 8.0 million

XVIPF Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 25.2 million 7.3 million
Dec. 31, 2025 24.5 million 8.6 million
Sept. 30, 2025 19.9 million 6.7 million
June 30, 2025 18.9 million 4.8 million

XVIPF

Price: $29

52 week price:
16.98
32.90

Earnings Per Share: 0.25 USD

P/E Ratio: 91.24

Exchange: PNK

Sector: Healthcare

Industry: Medical Devices

Market Capitalization: 925.8 million

Links: